Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (symbol: CGEN) is a cutting-edge drug discovery company specializing in developing therapeutic proteins and monoclonal antibodies to meet critical needs in immunology and oncology. By leveraging a sophisticated infrastructure of proprietary scientific insights, predictive platforms, algorithms, and machine learning systems, Compugen excels in in silico (computer-based) prediction and selection of promising product candidates for its pipeline program.
Compugen's business model is robust and diversified, encompassing partnerships and collaborations for the further development and commercialization of its product candidates. These collaborations typically offer milestone payments and royalties on product sales, providing Compugen with multiple revenue streams. The company's U.S. subsidiary, based in South San Francisco, focuses on developing monoclonal antibodies.
At the core of Compugen's operations is its clinical-stage therapeutic discovery and development efforts, primarily in cancer immunotherapy. Its comprehensive immuno-oncology pipeline includes four clinical-stage programs, each targeting immune checkpoints discovered through computational methods. Notable programs include COM701, COM902, and bapotulimab. These programs are designed to tackle various mechanisms of immune resistance, with a particular focus on myeloid targets.
Recent achievements highlight Compugen's forward momentum. The company announced it would release its fourth quarter and full-year 2023 financial results on March 5, 2024. Compugen's President and CEO, Anat Cohen-Dayag, emphasized the company's strong financial footing, collaboration successes, and the anticipated catalytic milestones in 2024.
Key partnerships enhance Compugen’s clinical progress. For instance, the company has a license agreement with Gilead Sciences for COM503, a first-in-class antibody program against IL-18 binding protein. This agreement includes a $60 million upfront payment and a $30 million milestone payment upon IND clearance.
Another significant partnership is with AstraZeneca, which is advancing a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 into Phase 3 development. This program, rilvegostomig, targets biliary tract cancer and nonsquamous non-small cell lung cancer. These collaborations underscore the extensive potential and validation of Compugen's computational discovery platform.
Compugen's financial health is robust, with a reported cash balance of $101.3 million as of March 31, 2024, ensuring operational funding into 2027. The company has demonstrated prudent financial management, achieving net revenues and reducing operational losses over time.
Headquartered in Israel, with additional offices in San Francisco, Compugen is listed on both Nasdaq and the Tel Aviv Stock Exchange, making it a prominent player in the biotech sector. For investors and stakeholders, Compugen represents a beacon of innovation and potential in cancer immunotherapy.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy firm, announced its participation in several upcoming investor conferences. Notable events include the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 AM ET, and the Jefferies Virtual Healthcare Conference on November 18, 2021, with a recording available from 3:00 AM ET. Additional engagements include the Truist Securities SITC Breakfast on November 13, JMP Securities Virtual C-Suite on November 29, and the JMP Securities Virtual Hematology Oncology Summit on December 7. For more details, visit www.cgen.com.
Compugen Ltd. (NASDAQ: CGEN) will release its third quarter 2021 financial results on November 12, 2021, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide a corporate update. Additionally, Compugen will present data at the Society for Immunotherapy of Cancer Annual Meeting from November 10-14, 2021, with eposters available on the same day as the earnings release. Compugen focuses on cancer immunotherapy, with lead candidates COM701 and COM902 in Phase 1 studies.
Compugen Ltd. (NASDAQ: CGEN) announced a $6 million milestone payment from AstraZeneca (NASDAQ: AZN) following the first patient dosing in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody for lung cancer. This event marks the advancement of Compugen's COM902 program into clinical trials, contributing to its pipeline expansion. To date, Compugen has received a total of $12 million from AstraZeneca under their 2018 license agreement, which could potentially yield up to $200 million in milestone payments and royalties on sales.
Compugen Ltd. (NASDAQ: CGEN) announced the presentation of new clinical and preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 10-14, 2021. Key presentations include the evaluation of COM902, an anti-TIGIT antibody, in patients with advanced solid tumors, and the results of COM701 in combination with other therapies. Both studies emphasize safety, tolerability, and pharmacokinetics. Compugen continues to advance its lead product candidates in cancer immunotherapy, as they navigate through Phase 1 studies.
Compugen Ltd. (NASDAQ: CGEN) announced that it will present at the Cantor Global Healthcare Conference on September 30, 2021, at 1:20 pm ET. The presentation will cover its advancements in cancer immunotherapy, particularly focusing on COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT. Both are in Phase 1 studies for treating solid and hematological tumors. A live webcast will be accessible via Compugen's website.
Compugen Ltd. (NASDAQ: CGEN) will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:00 am ET. The presentation will be available via a live webcast on Compugen's website, with a replay accessible afterward.
Compugen is focused on cancer immunotherapy, with key products like COM701 and COM902 in Phase 1 studies. Based in Israel, the company utilizes predictive discovery platforms to create novel drug targets.
Compugen Ltd. (NASDAQ: CGEN) announced the advancement of a bispecific antibody derived from COM902 into clinical development by AstraZeneca, which will evaluate AZD2936 in patients with advanced non-small cell lung cancer. AstraZeneca holds exclusive rights for the development of products based on COM902, while Compugen retains rights for monotherapies and combination treatments. Compugen has received a $10 million upfront payment and $2 million in milestone payments, with a potential of up to $200 million in future milestones.
Compugen Ltd. (NASDAQ: CGEN) released its financial results for Q2 2021, reporting a net loss of $9.5 million, up from $6.2 million in Q2 2020. R&D expenses rose to $6.8 million from $4.4 million year-over-year. Compugen initiated three clinical studies for its anti-PVRIG, anti-TIGIT, and anti-PD-1 combination therapies, highlighting its leadership in the DNAM axis space. Cash and equivalents totaled approximately $111 million as of June 30, 2021. Upcoming data readouts are expected to enhance the company's clinical data foundation.
Compugen Ltd. (CGEN) has announced the dosing of the first patient in its Phase 1/2 study, which evaluates the triple combination of COM701, Opdivo®, and BMS-986207. This study aims to assess the safety, tolerability, and preliminary antitumor activity of this novel therapy targeting PVRIG, TIGIT, and PD-1 pathways, believed to enhance anti-tumor immune responses. The cohort expansion phase focuses on specific patient populations, with preliminary data expected by Q4 2021. Compugen partners with Bristol Myers Squibb for this innovative immunotherapy approach.
Compugen Ltd. (CGEN) has announced the dosing of the first patient in a Phase 1 clinical study assessing the combination of its anti-TIGIT antibody, COM902, and anti-PVRIG antibody, COM701, in patients with advanced malignancies. The study aims to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity in patients who have exhausted standard therapies. Initial results from the COM902 monotherapy study are expected in Q4 2021. Compugen's strategy focuses on expanding immunotherapy effectiveness through dual blockade of PVRIG and TIGIT pathways.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen Ltd's primary business focus?
What makes Compugen unique in the biotech industry?
Who are Compugen's key partners?
What are some of Compugen's notable products?
What recent financial milestones has Compugen achieved?
Where is Compugen Ltd headquartered?
On which stock exchanges are Compugen's shares listed?
What are some of Compugen's recent achievements?
What is the significance of Compugen’s computational discovery platform?
What is Compugen's approach to advancing its pipeline?
